恩他卡朋联合左旋多巴治疗帕金森病的疗效及安全性

Therapeutic effect and safety of entacapone combined with levodopa on Parkinson's disease

目的探讨恩他卡朋联合左旋多巴治疗帕金森病的疗效及治疗安全性。方法回顾性分析收治的70例帕金森病患者的治疗方案,将其分为对照组(n=38、接受左旋多巴治疗)、研究组(n=32、接受恩他卡朋联合左旋多巴治疗),持续治疗12周后评估疗效。对比两组患者的治疗效果,血清氧化应激指标[活性氧(ROS)、丙二醛(MDA)、还原型谷胱甘肽(GSH)、超氧化物歧化酶(SOD)]及脑啡肽(β-内啡肽、亮脑啡肽)水平差异,评估治疗安全性。结果治疗后,研究组临床有效率显著高于对照组(χ^(2)=4.015,P=0.045);血清中ROS、MDA的水平显著低于对照组,GSH、SOD的水平高于对照组(t=5.104、4.182、5.034、7.495,P=0.000);血清中β-内啡肽、亮脑啡肽的含量高于对照组患者(t=7.087、7.121,P=0.000)。治疗期间,研究组患者胃肠道反应、“开关”现象、日内波动现象、排尿困难等不良反应发生率低于对照组(χ^(2)=4.159、4.983、4.015、4.534,P=0.041、0.026、0.045、0.033);两组间便秘、失眠症等不良反应发生率的差异无统计学意义(χ^(2)=0.554、1.205,P=0.456、0.272)。结论恩他卡朋辅助治疗帕金森病,有助于疗效提升,且具有良好的用药安全性。

Objective To investigate the efficacy and safety of entacapone combined with levodopa in the treatment of Parkinson's disease.Methods 70 cases of Parkinson's disease in our hospital were retrospectively analyzed,they were divided into the control group(n=38,underwent levodopa treatment)and the research group(n=32,underwent entacapone combined with levodopa treatment).Curative effect was evaluated after 12 weeks of continuous treatment.The therapeutic effects,serum levels of oxidative stress indicators[reactive oxygen species(ROS),malondialdehyde(MDA),reduced glutathione(GSH),superoxide dismutase(SOD)]and enkephalin(beta-endorphin,leucopentin)were compared between the two groups to evaluate the safety of treatment.Results After treatment,the clinical effective rate of study group was higher than that of control group(χ^(2)=4.015,P=0.045);levels of ROS and MDA in study group were lower than those of control group,and levels of GSH and SOD were higher than those of control group(t=5.104,4.182,5.034,7.495,P=0.000);levels of serum beta-endorphin and leucopentin were higher than those of control group(t=7.087、7.121,P=0.000).During treatment,incidence of adverse reactions such as gastrointestinal reactions,switching,intra-day fluctuations and dysuria in study group were lower than those in control group(χ^(2)=4.159,4.983,4.015,4.534,P=0.041,0.026,0.045,0.033).There were no significant difference in incidence of adverse reactions such as constipation and Insomnia between two groups(χ^(2)=0.554,1.205,P=0.456,0.272).Conclusion Entacarbon is an adjuvant therapy for Parkinson's disease,which is helpful to improve the curative effect and has good medication safety.